<DOC>
	<DOCNO>NCT01842490</DOCNO>
	<brief_summary>No serum biomarker qualify clinical use . However several biomarkers , especially marker inflammatory proteolytic activity seem promise identification vulnerable plaque . Moreover , recent study confirm contrast-enhanced ultrasound imaging ( CEUS ) visualize intraplaque neovascularization represent plaque vulnerability . In study try identify indicator analysis relationship plaque neovascularization see CEUS well know biomarkers serum matrix metalloproteinase ( MMP ) -2 , MMP-9 , cathepsin family ( L , S , V ) , cystatin C , lipoprotein phospholipase A2 , hs-crp</brief_summary>
	<brief_title>Serum Biomarker Plaque Vulnerability Contrast Ultrasound Carotid Artery</brief_title>
	<detailed_description />
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<criteria>patient carotid plaque size 2mm carotid ultrasound know allergy albumin , ultrasound contrast agent patient history carotid endarterectomy carotid stent acute myocardial infarction , cardiogenic shock connective tissue disease malignancy creatinine clearance low 30ml/min history dialysis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Biomarker</keyword>
	<keyword>Carotid enhance ultrasound</keyword>
	<keyword>Intraplaque neovascularization</keyword>
</DOC>